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Abstract
JC polyomavirus (JCV) carriers with a compromised immune system, such as in HIV, or subjects on immune-modulating
therapies, such as anti VLA-4 therapy may develop progressive multifocal leukoencephalopathy (PML) which is a lytic
infection of oligodendrocytes in the brain. Serum antibodies to JCV mark infection occur only in 50–60% of infected
individuals, and high JCV-antibody titers seem to increase the risk of developing PML. We here investigated the role of
human leukocyte antigen (HLA), instrumental in immune defense in JCV antibody response. Anti-JCV antibody status, as a
surrogate for JCV infection, were compared to HLA class I and II alleles in 1621 Scandinavian persons with MS and 1064
population-based Swedish controls and associations were replicated in 718 German persons with MS. HLA-alleles were
determined by SNP imputation, sequence specific (SSP) kits and a reverse PCR sequence-specific oligonucleotide (PCR-SSO)
method. An initial GWAS screen displayed a strong HLA class II region signal. The HLA-DRB1*15 haplotype was strongly
negatively associated to JCV sero-status in Scandinavian MS cases (OR = 0.42, p = 7610215) and controls (OR= 0.53,
p = 261025). In contrast, the DQB1*06:03 haplotype was positively associated with JCV sero-status, in Scandinavian MS cases
(OR= 1.63, p = 0.006), and controls (OR= 2.69, p = 161025). The German dataset confirmed these findings (OR= 0.54,
p = 161024 and OR= 1.58, p = 0.03 respectively for these haplotypes). HLA class II restricted immune responses, and hence
CD4+ T cell immunity is pivotal for JCV infection control. Alleles within the HLA-DR1*15 haplotype are associated with a
protective effect on JCV infection. Alleles within the DQB1*06:03 haplotype show an opposite association. These
associations between JC virus antibody response and human leucocyte antigens supports the notion that CD4+ T cells are
crucial in the immune defence to JCV and lays the ground for risk stratification for PML and development of therapy and
prevention.
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Introduction
Progressive multifocal leukoencephalopathy (PML) was first
described neuropathologically during the fifties by Karl Erik
A˚stro¨m [1]. It took until 1971 when JC virus (JCV) was isolated
from brain tissue of a patient with PML, since then JCV was
accepted as the causative agent of PML [2]. PML used to be a rare
demyelinating disease of the central nervous system, mainly seen
in patients with lymphoproliferative disease or AIDS. Now several
different drugs that interfere with immune functions, such as
natalizumab, efalizumab, mycophenolate mofetil, fumaric acid,
rituximab, tacrolimus, and possibly azathioprine, cyclosporine and
cyclophosphamide have been associated with an increased risk of
developing PML. For natalizumab and efalizumab the strongest
associations were seen in patients without an underlying disease
that predispose for PML itself [3–7]. Thus, it is of major
importance to develop measures to prevent or treat the condition,
including understanding of factors allowing persons to acquire the
virus, as carriers, a requisite for later risk for PML.
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In patients with multiple sclerosis (MS) treated with natalizumab
previous immunosuppressive therapy, an increased duration of
therapy, and the positive detection of anti-JCV IgG antibodies as
surrogate for the infection with JCV have been established as risk
factors for PML [8–12]. The anti-JCV antibody status in MS
patients is determined by a commercial two step-ELISA. Around
40–50% of the adults are anti-JCV antibody negative [11,13–15].
The cut-off of the commercial assay have been validated in large
multicentre cohorts of MS patients with data on JC viruria
available, and the false negative rate (sero-negative, but DNA
excretion in urine) was estimated with around 2.5% [9–11]. In
contrast, a recent study that also measured JCV excretion in urine
in a comparably small study population (n= 67) indicated a much
higher false negative rate of 37%, however, these cases displayed
considerably lower JCV DNA copy numbers in the urine.
Hypothetically, a vast majority of persons might be exposed to
an ubiquitous virus such as JCV, proposed as contamination
marker for human excretions, [16] but differ in replicative activity
of a persistent asymptomatic infection, and potentially connected
to this, the individual level of immune response to the virus. This
view would fit with recent serological observations of a continuous
anti-JCV reactivity in larger populations, [17] and might imply
that actually not the true absence of the JCV infection, but rather
the level of the replicative activity of the persistent JCV infection
determines the individual risk of developing PML [18]. This risk
might then critically depend on host genetic factors that determine
the immune response to the virus, and protect from e.g. the spread
of the virus from places of peripheral persistency or latency to the
brain. Genes of particular interest in this respect are the HLA class
I and class II genes where different variants with different peptide
presenting abilities may affect the effectiveness of CD4+ and
CD8+ T cell immune defence.
Our aim was therefore to test the host genetic regulation of HLA
genes in the immune response to JCV. We used anti-JCV antibody
status and anti-JCV antibody levels as surrogate for the
identification of persons carrying a JCV infection in significant
and clinically relevant levels and tested association to HLA class I
and class II genes.
Results
Clinical characteristics and demographic data of the included
patients and controls are displayed in table 1. Anti-JCV antibody
status and levels were determined in the same laboratory for all
individuals with an ELISA based method [9].
Author Summary
JC virus infection can lead to progressive multifocal
leukoencephalopathy in individuals with a compromised
immune system, such as during HIV infections or when
treated with immunosuppressive or immunomodulating
therapies. Progressive multifocal leukoencephalopathy is a
rare but potentially fatal disease characterized by progres-
sive damage of the brain white matter at multiple
locations. It is therefore of importance to understand the
host genetic control of response to JC virus in order to
identify patients that can be treated with immunomodu-
lating therapies, common treatments for autoimmune
diseases, without increased risk for progressive multifocal
leukoencephalopathy. This may also lead to development
of preventative or curative anti-JC virus therapies. We here
identify genetic variants being associated with JC virus
antibody development; a negative association with the
human leucocyte antigen DRB1*15-DQA1*01:02-
DQB1*06:02 haplotype and a positive association with
the DRB1*13-DQA1*01:03-DQB1*06:03 haplotype among
controls and patients with multiple sclerosis from Scandi-
navia. We confirmed the associations in patients with
multiple sclerosis from Germany. These associations
between JC virus antibody response and human leucocyte
antigens imply that CD4+ T cells are crucial in the immune
defence and lay the ground for development of therapy
and prevention.
Table 1. Demographic information.
Scandinavian MS Swedish controls German MS*
Total number genotyped 1621 1064 718
JCV positive (%) 955 (59) 706 (66) 406 (57)
Median JCV nOD in positive individuals 0.398 0.455 0.552
Age at sampling (mean) 39.6610.6 41.2611.3 39.3610.1
% women 72 74 74
Number of individuals with HLA-genotypes and serostatus (JCV
seropositivity)
HLA-A 1599 (58.9%) 1059 (66.4%) 655 (56.2%)
HLA-B 1417 (59.2%) 903 (66.0%) 678 (56.0%)
HLA-C 1306 (59.3%) 954 (66.6%) 699 (56.4%)
HLA-DRB1 1551 (59.4%) 1059 (66.4%) 631 (55.6%)
HLA-DQB1 1452 (58.9%) 963 (66.3%) 698 (56.3%)
HLA-DQA1 1409 (58.6%) 908 (65.9%) 690 (56.7%)
With GWAS genotypes (JCV seropositivity) 634 (59.0%) 465 (63.2%) 718 (56.5%)
Demographic information on 1621 Scandinavian MS cases, 1064 Swedish controls and 718 German MS cases with anti-JCV antibody status, anti-JCV nOD antibody levels
and HLA-genotypes (from either HLA-A, B, C, DRB1, DQB1, or DQA1). *Since all individuals were GWAS genotyped, they had genotype information for all HLA-loci, the
numbers shown are the number that passed the quality score $0.70 for both alleles for imputed HLA genotypes.
doi:10.1371/journal.ppat.1004084.t001
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Figure 1. Association between JCA antibody response and markers in the Human Leuococyte region on chromosome 6. A Plot of the
HLA region from the meta-analysis (random effects model) of the association between GWAS markers and JCV serostatus in the Scandinavian
(n = 634) and German (n = 718) MS cases and the Swedish controls (n = 465) on chromosome 6. The horizontal line represent a p-values of and
161028. All analyses were adjusted for gender, age at sampling, and principal components. The most significant SNP is rs34454237 (p,4610214)
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In this study we selected the HLA complex for scrutiny in view
of its potent immune regulatory functions. We performed a meta-
analysis of association of markers on chromosome 6 for both anti-
JCV antibody status and normalized anti-JCV antibody levels
(anti-JCV nOD) of results obtained in the three separate cohorts of
individuals shown in table 1. This indicated a strong association
signal in the HLA class II region for both anti-JCV antibody status
and anti-JCV nOD values (figure 1). The most significant markers
for the two analyses (rs34454257 for the anti-JCV antibody status
and rs3129860 for anti-JCV nOD values) map 42.6 and 145.7 kb
upstream of the HLA-DRB1 gene in the direction of the HLA class
I genes.
With this association signal on chromosome 6p21, it was of
interest to determine the particular class II gene variants which
were associated. Several HLA-alleles showed association to anti-
JCV antibody status in both Scandinavian MS cases and controls
(Table 2). The table is organised based on common established
extended haplotypes found in the Caucasian population [19–21].
It is noteworthy that the DRB1*15-DQA1*01:02-DQB1*06:02-
haplotype, the most strongly associated MS genetic risk factor, was
found to be negatively associated with the positive detection of
anti-JCV antibodies. The OR for DRB1*15 was 0.42 in
Scandinavian MS cases and 0.53 in controls. This association
was replicated in German MS cases (OR for DRB1*15 0.54
Table 3). Other alleles in this haplotype, DQB1*06:02 and
DQA1*01:02, also showed strong protective associations, as
expected, since they are in LD with DRB1*15:01. In contrast,
the DRB1*13-DQA1*01:03-DQB1*06:03-haplotype was positively
associated with anti-JCV antibody status, with an OR=1.62 in
Scandinavian MS cases, OR=1.55 in Swedish controls (Table 2)
and OR=1.58 in German MS cases (Table 3). In addition the
DRB1*03-DQA1*05-DQB1*02 and DQA1*05-DQB1*03:01 haplo-
types showed a positive association to anti-JCV antibody status,
while the DQA1*05-DQB1*01:01-haplotype was negatively associ-
ated with anti-JCV antibody status among controls.
The DRB1*15-DQA1*01:02-DQB1*06:02-haplotype also
showed an association to lower anti-JCV nOD levels in a linear
regression analysis among JCV seropositive individuals, with a
significance level of p#0.001 in the Scandinavian cohorts
(Table 4). For DQB1*06:02 beta was between 20.218 and
20.366 in the different cohorts (Table 4 and 5).
DRB1*13 showed an association to higher anti JCV nOD levels
among Scandinavian MS cases, p = 0.02, beta = 0.197, but not in
German MS cases or Swedish controls (Table 4 and 5). In addition
DQB1*03:01 and DQA1*05 showed an association to higher
transformed anti-JCV nOD levels among Swedish controls
(Table 4).
Most of the HLA associations to both anti-JCV antibody status
and anti-JCV nOD levels remained similar when other nominally
associated HLA alleles for the same gene are included in the
regression analysis (Table 2 to 5).
The OR for the association of the presence of DRB1*15 and for
DRB1*15 homozygotes for JCV antibody status did not differ,
suggestive of a dominant DRB1*15 effect (Figure 2A). Conversely,
the DRB1*13 homozygotes showed a slightly stronger association
compared to presence of DRB1*13, although the 95%CI do
overlap. DRB1*13/15 heterozygotes were not significantly
associated with JCV seropositivity indicating that the effect of
the two haplotypes counteract each other. Similar results were
seen for the DQA1 locus (Figure 2B), but here the DQA1*01:03/
05 heterozygotes are associated with an OR as high as 5.23.
Consistent with the effect on the qualitative anti-JCV status, the
DRB1*15 haplotype appeared to act dominantly also on anti-JCV
nOD levels as presence of DRB1*15 showed a similar association
to DRB1*15 homozygotes, while the DRB1*11 haplotype had an
additive effect (Table 6). The effect of these two haplotypes cancel
each other out as DRB1*11/15 heterozygotes showed no
association to anti-JCV nOD levels.
We reanalysed the association of SNPs on chromosome 6 to
anti-JCV antibody status and anti-JCV nOD levels when including
all HLA alleles that remained associated in the multivariate
analysis as covariates. This lead to an almost complete abolish-
ment of the association peak on chromosome 6, with the most
significant remaining associations being p= 0.0001 for a handful of
markers (data not shown). This indicates that the association we
observed in the HLA region was almost completely explained by
the HLA alleles listed in tables 2–4.
Discussion
We here demonstrate a host genetic HLA complex mediated
influence on anti-JCV antibody status and anti-JCV antibody
levels as surrogate for the susceptibility of the infection with JCV
or the activity of the infection with JCV, respectively.
We report a strong negative association with anti-JCV antibody
positivity, and to a lesser extent, to anti-JCV nOD levels, for the
HLA-DRB1*15-DQA1*01:02-DQB1*06:02-haplotype in all three
datasets. In contrast, the DRB1*13-DQA1*01:03-DQB1*06:03-
haplotype is associated to increased signs of JCV carriage as
assessed serologically. We further find that the DRB1*
15-DQA1*01:02-DQB1*06:02 haplotype acts dominantly, one
copy being sufficient to reduce the ability to form anti-JCV
antibodies while the DRB1*13-DQA1*01:03-DQB1*06:03 haplo-
type acts in an additive fashion. Neither of the haplotypes
dominates over the other. A recent study demonstrated consider-
able variation in which JCV peptides were recognized by T cells
[22]. A most straight forward interpretation of the present findings
is that the DRB1*15:01 haplotype displays class II molecules that
are especially able to present JCV antigens/peptides that are
instrumental in activating CD4+ T cells that support the
elimination or control of the virus upon exposure to the host.
Hence, the opposite would be valid for the haplotype associated
with increased carriage of the JCV. Thus hypothetically a large
proportion of those persons being sero-negative might have
encountered the virus, but had an efficient immune response
following primary infection, with low viral turnover or the lack of
viral persistency, and low anti-JCV IgG as consequence.
Recent serological studies support such a concept: antibody
reactivity as measured by ELISA resembles a continuum from
non-reactive to highly reactive in particular in persons not
excreting the virus in urine [9]. This led to the introduction of a
second-step confirmation test when determining the anti-JCV
sero-status. However, this pattern of continuous reactivity is also
seen with alternative assay formats, which suggest that a vast
majority of persons have been exposed to JCV, but have a level of
which maps 42.6 kb from the HLA-DRB1 gene towards the HLA class I genes. B Plot of the HLA region from the meta-analysis (random effects model)
of the association between GWAS markers and transformed anti-JCV nOD levels in the anti-JCV antibody positive Scandinavian (n = 374) and German
(n = 294) MS cases and the Swedish controls (n = 406). The horizontal lines represent a p-value of and 161028. All analyses adjusted for gender, age at
sampling, and principal components. The locations of the HLA-A, -C, -B, -DRB1, -DQA1 and -DRB1 loci are noted using genome build 36. The most
significant SNP is rs3129860 (p,161027) which maps 145.7 kb from the HLA-DRB1 gene in the direction of the HLA class I genes.
doi:10.1371/journal.ppat.1004084.g001
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the antibody response to JCV below the assay cut-off, possibly due
to an efficient control of the virus with low viral turn-over [13,17].
This would also explain the higher false negative rate of serological
studies observed in recent publications [23,24].
Although CD8+ cells, restricted by class I molecules are critical
in eliminating virus infected cells, antigen specific CD4+ HLA class
II restricted cells are crucial for providing T cell help through a
variety of cytokines and activation of antigen presenting dendritic
cells [25]. The findings may pave the way for finding epitopes in
JCV critical for immune defence which could impact on
vaccination strategies. Any direct clinical implications of the data,
or use, for example in risk stratifications, remain to be determined.
The DRB1*13-DQA1*01:03-DQB1*06:03-haplotype shows a
positive association to anti-JCV antibody serostatus, and was also
to higher anti-JCV nOD levels. Hypothetically, a less effective
viral immune control with higher viral turnover may be consistent
with a chronically higher stimulation of the B cell arm of the
immunity resulting in higher antibody levels. This might help us
understand why patients that develop PLM during therapy with
natalizumab had increased anti-JCV antibody levels already prior
to development of PML, and why it might be rational to include
the level of the anti-JCV response into PML risk stratification
strategies [26].
Recent data suggests that PML-specific viral mutations are
acquired intra-individually e.g. in the VP1-region and the
regulatory region of the viral genome [27,28]. It is tempting to
speculate that viral PML-specific mutations, although being a
random event, are more likely to occur in persons with an
inefficient control of the infection with JCV. The host genetic data
presented here might therefore be a first step helping to
understand how the interplay of host- and viral genetic factors
might lead to the development of PML in some, but not all persons
exposed to certain immunosuppressive therapies. Our study is
however lacking a sufficient number of cases of PML and is
therefore not designed and empowered to test this directly.
There is one previous paper studying the HLA association to
PLM [29]. In this paper 123 Caucasian PML cases, the majority
whom were HIV positive, were compared with a large group of
HIV positive individuals. The study was limited to the association
of HLA class I antigens. While A3 was found to be nominally
negatively associated with PML, B18 was found to be positively
associated. We do not find any of these alleles associated with anti-
JCV antibody formation in our study. However, the A3 association
to PML possibly is explained by the same effect as the DRB1*15-
DQA1*01:02-DQB1*06:02 association we see in our study,
considering that A3 can be present on the same extended
Table 3. HLA-associations to anti-JCV antibody status among German MS patients.
Frequency
(JCV Ab pos/neg) Crude Multivariate*
Allele p-value OR(95% CI) p-value OR(95% CI)
Haplotype DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*24
DQB1*06:02 49.1/64.7 8 e-5 0.53(0.39–0.73) 4 e-4 0.56(0.40–0.77)
DQA1*01:02 51.3/64.3 0.002 0.60(0.44–0.83) 0.009 0.64(0.46–0.90)
DRB1*15 49.5/64.6 1 e-4 0.54(0.39–0.74) 6 e-4 0.57(0.41–0.78)
B*07 51.1/59.7 0.01 0.65(0.47–0.90) 0.01 0.65(0.47–0.90)
A*24 56.9/56.3 0.63 1.10
Haplotype DQB1*06:03-DQA1*01:03-DRB1*13-B*44-C*?-A*02
DRB1*13 63.9/54.7 0.03 1.58(1.06–2.37) 0.14
Haplotype DQB1*02-DQA1*05-DRB1*03-B*08-C*07-A*1
DQB1*02 58.6/55.3 0.53 1.11
DQA1*05 60.8/53.1 0.02 1.45(1.05–2.01) 0.11
DRB1*03 63.8/54.5 0.07 1.46
B*08 59.0/55.7 0.21 1.06
A*01 59.1/55.0 0.52 1.12
Haplotype DQB1*05-DQA1*01:01-DRB1*01-B*07-C*07-A*24
DQB1*05 60.8/53.1 0.52 0.89
DQA1*01:01 54.8/56.9 0.60 0.90
Haplotype DQB1*03:01-DQA1*05-DRB1*11-B*51-C*05-A*02
DQB1*03:01 60.6/54.5 0.04 1.43(1.02–2.00) 0.20
DQA1*05 60.8/53.1 0.02 1.45(1.05–2.01) 0.11
Results from the association analysis between HLA-alleles and JCV seropositivity in the German MS cases. The frequencies in the second column are the frequencies of
HLA alleles among JCV Ab seropositive and seronegative respectively. In the crude analysis each allele was analysed on its own, adjusted for gender and age. The
analysis was performed in PLINK 1.07 [49]. The analysis was adjusted for age at sampling, significant principal components from EIGENSTRAT analysis of genomewide
SNP data and gender. Age was included as a continuous covariate. *Multivariate: all nominally significant alleles from the same gene in the same model, adjusted for
age and gender.
DQB1*06:03 and DQA1*01:03 were not included in the analysis because the allele frequency was below 5%.
Common extended HLA haplotypes were selected from those published in the literature for the Caucasian population [19–21]. Alternative common DRB1*15
haplotypes DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*02, DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*03, DQB1*06:02-DQA1*01:02-DQB1*15-B*51-C*?-A*02,
DQB1*06:02-DQA1*01:02-DRB1*15-B*51-C*?-A*11. The DQB1*03:01-DQA1*05-DRB1*11-B*51-A*02 haplotype exist with many different C alleles, C*05 not being the most
common one.
doi:10.1371/journal.ppat.1004084.t003
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haplotype. Studies in larger cohorts of PML patients with
appropriate controls testing the association of class II antigens
are warranted. A recent investigation has studied the stimulation
of CD4+ T cells by pools of JCV peptides among healthy donors
with different HLA-DRB1 alleles [22]. For haplotypes where we see
an increased OR for sero-status and positive correlation to JCV-
Ab levels (DRB1*13 and DRB1*03) they observe reduced
stimulation of CD4+ cells, while the opposite was true for
DRB1*15. Hence, both antibody response and T-cell response to
JCV infection are affected by HLA-class II antigens, which is
consistent with our observations of potent HLA class II gene
variant effects in large cohorts of persons.
HLA associations to some viral infections have been seen
previously. The HLA class II genes were recently reported as host
genetic factors influencing the IgG response to EBNA1, an Epstein
Barr virus-related protein [30]. In addition, there are well
documented class II allelic influences on Hepatitis C [31] and
recently a highly associated SNP in the HLA region was
demonstrated in relation to human papilloma virus infection [32].
HLA class II associations have also been seen in chronic hepatitis B
infections as well as response to hepatitis B vaccination [33–35].
Association to the HLA class I related MICB gene have also been
reported to hypovolemic shock caused by dengue viral infection and
HIV viral load [36,37]. Another MIC gene, MICA has been
associated to hepatitis C virus induced hepato cellular carcinoma
[38]. In our data, after adjusting the association for HLA class II
associated alleles the most strongly associated marker in the class I
region is rs3094014 (p,0.02) which is in LD with both theMICB (r2
0.76 for rs3132468 associated with dengue fever) andMICA (r2 0.90
for rs2596542 reported to be associated with hepatitis C virus
induced hepato cellular carcinoma) using European 1000 genomes
and HapMap data and may therefore represent the same signal.
Interestingly, the DRB1*15 haplotype is also the most strongly
associated genetic risk factor for MS [39]. Consistent with this, the
Table 4. HLA-association to transformed JCV nOD levels in Scandinavian cohort.
Scandinavian MS cases Swedish Controls
Crude Multivariate* Crude Multivariate*
Allele
Median nOD JCV
Ab (pos/neg){ p-value beta p-value beta
Median nOD JCV
Ab (pos/neg){ p-value beta p-value beta
Haplotype DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*24
DQB1*06:02 0.357/0.453 0.001 20.218 0.001 20.218 0.322/0.488 8 e-5 20.366 0.0004 20.333
DQA1*01:02 0.360/0.476 0.001 20.233 0.001 20.233 0.372/0.492 0.004 20.252 0.02 20.149
DRB1*15 0.356/0.452 0.001 20.238 0.006 20.188 0.308/0.482 5 e-6 20.399 5 e-6 20.399
Haplotype DQB1*06:03-DQA1*01:03-DRB1*13-B*44-C*?-A*02
DRB1*13 0.495/0.363 0.02 0.197 0.08 0.139 0.459/0.450 0.24 0.098
Haplotype DQB1*03:01-DQA1*05-DRB1*11-B*51-C*05-A*02
DQB1*03:01 0.476/0.398 0.08 0.153 0.523/0.427 0.05 0.171 0.06 0.151
DQA1*05 0.412/0.399 0.11 0.150 0.528/0.421 0.04 0.172 0.16 0.087
Results from the linear regression analysis of the association between HLA-alleles and JCV nOD levels. Only alleles that are nominally significant (p,0.05) alleles in any
cohort in this or table 5 are presented. P-values that reach nominal significance, 0.05 are marked in bold. The median nOD levels are given among individuals positive or
negative for respective HLA allele. In the crude analysis each allele was analysed on its own, adjusted for gender and age. Age at sampling was divided into four
categories, 18–29, 30–39, 40–49, and 50 and older, with group 40–49 as the reference. The analysis was performed in R version 2.15.1 [50]. *Multivariate: all nominally
significant alleles from the same gene in the same model, adjusted for age and gender. {Median nOD is given among individuals positive or negative for respective HLA
allele.
Common extended HLA haplotypes were selected from those published in the literature for the Caucasian population [19–21]. Alternative common DRB1*15
haplotypes DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*02, DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*03, DQB1*06:02-DQA1*01:02-DRB1*15-B*51-C*?-A*02,
DQB1*06:02-DQA1*01:02-DRB1*15-B*51-C*?-A*11. The DQB1*03:01-DQA1*05-DRB1*11-B*51-A*02 haplotype exist with many different C alleles, C*05 not being the most
common one.
doi:10.1371/journal.ppat.1004084.t004
Table 5. HLA-association to transformed JCV nOD levels in
German MS patients.
Allele Median nOD JCV Ab (pos/neg) p-value beta
Haplotype DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*24
DQB1*06:02 0.480/0.598 0.007 20.276
DQA1*01:02 0.508/0.633 0.01 20.256
DRB1*15 0.506/0.596 0.04 20.213
Haplotype DQB1*06:03-DQA1*01:03-DRB1*13-B*44-C*?-A*02
DRB1*13 0.471/0.572 0.18 20.168
Haplotype DQB1*03:01-DQA1*05-DRB1*11-B*51-C*05-A*02
DQB1*03:01 0.634/0.535 0.07 0.200
DQA1*05 0.596/0.526 0.48 0.073
Results from the linear regression analysis of the association between HLA-
alleles and JCV nOD levels. Only alleles that are nominally significant (p,0.05)
alleles in any cohort in this or table 4 are presented. P-values that reach nominal
significance, 0.05 are marked in bold. The median nOD levels are given among
individuals positive or negative for respective HLA allele. Each allele was
analysed on its own, adjusted for age at sampling, significant principal
components from EIGENSTRAT analysis of genomewide SNP data and gender.
Age was included as a continuous covariate. The analysis was carried out in
PLINK 1.07 [49]. As only alleles on the DQB1*06:02-DQA1*01:02-DRB1*15
haplotype were significant no multivariate analysis was performed. * Median
nOD is given among individuals positive or negative for respective HLA allele.
Common extended HLA haplotypes were selected from those published in the
literature for the Caucasian population [19–21]. Alternative common DRB1*15
haplotypes DQB1*06:02-DQA1*01:02-DRB1*15-B*07-C*07-A*02, DQB1*06:02-
DQA1*01:02-DRB1*15-B*07-C*07-A*03, DQB1*06:02-DQA1*01:02-DRB1*15-B*51-
C*?-A*02, DQB1*06:02-DQA1*01:02-DRB1*15-B*51-C*?-A*11. The DQB1*03:01-
DQA1*05-DRB1*11-B*51-A*02 haplotype exist with many different C alleles, C*05
not being the most common one.
doi:10.1371/journal.ppat.1004084.t005
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Figure 2. Analysis of association between HLA genotypes and anti-JCV antibody status in joint analysis of Swedish controls,
Scandinavian and German MS patients. A Odds ratio (OR) for DRB1 alleles and genotypes from logistic regression analyses performed in R
version 2.15.1 [50]. The analyses were adjusted for gender, cohort (Swedish controls, Scandinavian MS patients or German MS patients) and age at
sampling. Age at sampling was divided into four categories, 18–29, 30–39, 40–49, and 50 and older, with group 40–49 as the reference. Error bars
JC Virus Infection Association to HLA Class II
PLOS Pathogens | www.plospathogens.org 8 April 2014 | Volume 10 | Issue 4 | e1004084
demographic data in our study suggests that anti-JCV antibody
positivity is somewhat lower among MS cases (59%), compared to
controls (66%, p= 0.02). A protection against the establishment of
a persistent JCV infection with positive detection of anti-JCV
antibodies provided by the DRB1*15 haplotype would then
explain the lower sero-prevalence among cases. The presence of
an association with the DRB1*15-haplotype in controls also
indicates that the association is not likely due to an aberrant
immune response to JCV infection in MS cases.
In conclusion, we here demonstrate strong associations of class
II gene variants on JCV infection. Hence, CD4+ T cells, restricted
by class II molecules are crucial in the host control of JCV
infection. Our data is of importance for a better understanding of
JCV infection and virus-host interactions, and might pave the way
for new developments for an improved PML risk stratification, and
preventive or curative future anti-JCV therapies.
Materials and Methods
Ethics statement
The study was approved by the regional ethical committees in
each country involved; Stockholm regional Ethical Review Board
(Sweden), the Ethical review boards at the Heinrich-Heine
Universita¨t Du¨sseldorf and the Technische Universita¨t Mu¨nchen
(Germany) and the Danish Ethical Committee Review Board for
Copenhagen and Frederiksberg (Denmark). All participants
provided written informed consent.
Patients and controls
A Scandinavian dataset consisting of 2015 Swedish persons with
MS from two separate studies EIMS [40] and IMSE [41] with
1259 population based controls, and 157 Danish MS patients
treated with natalizumab in Copenhagen. HLA-genotypes and
anti-JCV antibody status were available for 1621 MS cases and
1064 controls (table 1).
A German dataset of 745 MS patients, 718 with GWAS data,
was used for replication. The cohort was recruited from multiple
sites in Germany and included persons treated with interferon-
beta for at least 6 months. GWAS genotyping for these MS cases
had been performed in the same laboratory with the same chip as
the Scandinavian datasets.
HLA and SNP-typing
HLA-genotypes came from three different sources. Low
resolution Sequence Specific amplification (Olerup, Saltsjo¨baden,
Sweden) [42] were for genotyping of 2115 Swedish cases and
controls for HLA-A, 2140 for HLA-DRB1, and 161 for HLA-C. For
HLA-B a Luminex based reverse PCR-SSO (One Lambda, Inc.,
Canoga Park, CA, USA) was used for 173 persons [39]. And
finally imputation either using HLA*IMP [43] with genotypes
from the IMSGC WTCCC2 MS GWAS, [44] or with
HLA*IMP:2 [45] using genotypes from the Immunochip [46]
was used. The former was used for both the Danish and German
cohort while both were used in the Swedish cohort. Imputed HLA
data was available for 1105 Swedish persons from the IMSGC
WTCCC2 and for 2220 Swedish persons using Immunochip
genotypes. In cases where the genotypes for any individual were
discordant between platforms, the following order of precedence
was used: classical, Immunochip imputed, GWAS imputed. A
quality value for allele probability of 0.7 was used as a threshold
for imputed HLA genotypes.
In this study we used SNP genotypes from MS GWAS study to
analyse association to the HLA region [44]. Genome-wide SNP
markers were genotyped as part of the IMSGC WTCCC2 MS
GWAS on the Human660-Quad chip, and genotype calling and
markers were quality controlled as previously described [44].
Cases with previous intravenous IgG treatment were excluded.
In the Scandinavian cohort all persons were of Scandinavian
ancestry, and all MS cases fulfilled the McDonald or Poser criteria
for MS. For the German MS cases, a total number of 749 cases
were GWAs genotyped; 25 persons were removed as they were
outliers in the principal component analysis (PCA), 4 were
removed due to unsuccessful genotyping, and 2 because of
natalizumab treatment at blood draw.
Anti-JCV antibody determination
JCV serology response was determined from plasma or serum
using a two-step assay, [9] performed at Focus Diagnostics (Cypress,
CA, USA) and sponsored by Biogen Idec (Cambridge, MA, USA).
In the first step of the ELISA assay optical density (OD) were
measured. Samples with OD.0.25 were considered positive while
samples with OD,0.10 were considered negative. For samples in
the intermediary interval (0.10–0.25) a second assay step was used to
determine the percentage of inhibition during a pre-incubation with
soluble JCV-like particles. Samples in this intermediary interval with
an inhibition .40% were considered positive while those with an
inhibition ,40% were classified as negative.
The assay has been estimated to have a false negative rate for
JCV carriage of 2–3%. For the quantitative analysis, normalised
OD values (nOD) from the first step ELISA were transformed
using rank based transformation in the GenABEL-package in R
[47].
represents 95% confidence intervals. OR below 1 are plotted as 21/OR. Grey indicates associations with p,0.05, white p.0.05. B Odds ratio (OR) for
DRB1 alleles and genotypes from logistic regression analyses performed in R version 2.15.1 [50]. The analyses were adjusted for gender, cohort
(Swedish controls, Scandinavian MS patients or German MS patients) and age at sampling. Age at sampling was divided into four categories, 18–29,
30–39, 40–49, and 50 and older, with group 40–49 as the reference. Error bars represents 95% confidence intervals. OR below 1 are plotted as21/OR.
Grey indicates associations with p,0.05, white p.0.05. DQA1*01:03 homozygotes are not included as this combination was so rare (0.4%).
doi:10.1371/journal.ppat.1004084.g002
Table 6. Association of HLA genotypes to transformed JCV
nOD levels in joint analysis of Swedish controls and
Scandinavian and German MS patients.
Allele/genotype Median nOD (pos/neg)* p-value beta
DRB1*15 0.364/0.487 4 e-9 20.189
DRB1*11 0.601/0.428 0.008 0.142
DRB1*11/11 1.037/0.442 0.04 0.769
DRB1*11/15 0.504/0.442 0.94 0.007
DRB1*15/15 0.329/0.456 0.005 20.181
Results from the linear regression analysis of the association between HLA-
alleles and genotypes and JCV nOD levels. The median nOD levels are given
among individuals positive or negative for respective HLA allele or genotype.
The analyses were performed in R version 2.15.1 [50] and were adjusted for
gender, cohort (Swedish controls, Scandinavian MS patients or German MS
patients) and age (as a continuous covariate).
* Median nOD is given among individuals positive or negative for respective
HLA allele or genotype.
doi:10.1371/journal.ppat.1004084.t006
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Statistical analysis
Association of GWAS-markers on chromosome 6 to anti-
viral antibodies. To generate principal components and control
for population stratification, an EIGENSTRAT analysis was
performed in each cohort separately, using Eigensoft [48]. This
analysis was performed after SNP-pruning with r2.0.2 were
removed using PLINK 1.07 [49]. All principal components with a
p-value below 0.05 were included as covariates in the regression
models. All persons considered as outliers in the PCA were removed.
Logistic regression analysis (for anti-JCV antibody status) and
linear regression analysis (for transformed anti–JCV nOD-levels
among JCV seropositive individuals) were performed in PLINK
1.07, adjusting for age, gender, and principal components. The
threshold for Hardy-Weinberg equilibrium test was p.0.001, and
minor allele frequency.0.05. We also ran the same analysis, where
we adjusted for all HLA-alleles associated with each outcome, with
p,0.05 in the final model as cut-off for inclusion.
A meta-analysis of the results from the different cohorts was
performed in PLINK 1.07, using both a fixed and a random effects
model.
Analysis of HLA-association. MS cases and controls were
analysed separately. Association to anti-JCV antibodies was tested
separately for alleles with a frequency higher than 5% separately.
As a second step, all nominally significant alleles from the same
HLA-gene were analysed in a multivariate regression model.
Association to anti-JCV serostatus was performed with logistic
regression, and association to transformed anti-JCV nOD-values
was performed with linear regression, in R [50] or PLINK 1.07
[49]. We adjusted for age at sampling and gender in all analyses.
For the German dataset, it was also possible to adjust for
principal components, but for the Scandinavian dataset, this was
not possible since the majority of samples were not genotyped with
genome wide markers.
For the analysis of effect of genotypes a joint analysis was
performed including all cohorts, in this analysis covariates for age
at sampling, gender and cohort were included.
Analysis of the data was carried out by Emilie Sundqvist, Eva
Albrecht and Ingrid Kockum.
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